HCW Biologics (HCWB)

• Market cap: $4.81M
• 1 day: -2.25%
• 5 days: -13%
• 1 month: -43.14%
• 3 months: -59.63%
• 6 months: -67.17%
• Year to date: -90.39%
• 1 year: -86.87%
• 5 years: -99.31%
• 10 years: -99.31%
• Sector: Healthcare
• Industry: Biotechnology

About: HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.

Employees: 36